{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Faadabrocitinibpart2-XYnVDX6J","width":444,"version":"1.0","type":"rich","title":"PART 2: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/ff3ae478-fae7-425a-8e98-9b37f58903d9/wl2.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"🎙️ Part 2 – Safety First 🛡️✨\n\nStill basking in Orlando sun, the crew zooms from efficacy fireworks to the serious stuff: a massive 2,500-patient-year integrated safety update on abrocitinib. Dr. Loo runs the numbers so you don’t have to:\n\nFour-and-a-half years of data, ~1,600 patients, ages 18–39 📊\nNo signal for VTE, MACE, or new malignancies despite the boxed-warning hype 🚫❤️‍🩹\nMain watch-out: shingles (herpes zoster) pops more in adults than teens\n\nDr. Liu’s playbook:\n\nBenefit → then risk. The speedy itch-relief first, mention nausea/headache next, finish with Black-Box context (RA ≠ AD, pan vs selective JAK).\nVaccinate, don’t vacillate. Shingrix before, during, or after start—flexibility wins.\nLab light-touch. CBC, LFTs, creatinine at baseline & month 1, then q6mo.\nDose dance. 200 mg for “put-out-the-fire” severe cases; 100 mg for teens, 65+ or comorbidity-heavy adults—with room to escalate.\n\n\n\n🎯 Learning Objectives\n\nSummarize long-term safety signals of abrocitinib in moderate–severe AD and contrast them with boxed-warning concerns.\nApply age- and risk-stratified dosing in shared decision-making for JAK initiation or escalation.\n\n#SkinAndJointsPodcast #AAD2025 #JAKSafety #Abrocitinib #EczemaCare #DermEd #ItchRelief #MedTwitter 🎧\n\n\n\nAbout Dr Wei Jing Loo, BSc (Med), MBBS, MRCP (UK), FRCP(c)\n\nDermatologist  | London, ON\n\nDr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. \n\nDr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals"}